Persistant atrial fibrillation requiring conversion of AF MedDRA version: 14.0 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disorders
Conditions
Interventions
Trade Name: Multaq
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: DRONEDARONE
CAS Number: 141626360
Current Sponsor code:
Sponsors
sanofi aventis
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria at screening: - Male or female adult aged 18 years or more, - Patient with persistent AF for more than 72 hours (documented by an ECG taken within the last 72 hours) for whom cardioversion, anti-arrhythmic treatment and anticoagulation treatment are indicated in the opinion of the Investigator (Note: patient may already be on anticoagulation treatment), - Naive of amiodarone treatment in the last three months prior to screening, - QTcB 70, hypertension, diabetes, prior cerebrovascular disease, left atrial diameter = 50 mm), - Signed written informed consent. Inclusion Criteria: to be checked at randomization - Outpatient and Inpatient. (except patients hospitalized during screening period for SAE). - Patient in sinus rhythm (Note: if cardioversion is performed on Day 1 prior to randomization, then the patient must be in sinus rhythm for at least one hour before randomization), - Patient under effective anticoagulation according to ACC/AHA/ESC AF treatment guidelines [18] verified by INR (target > 2). INR should be closely monitored after initiating dronedarone in patients taking vitamin K antagonist as per their label. - QTcB =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: •Exclusion criteria at screening: - Contraindication to oral anticoagulation, - Any documented AF episode motivating inclusion in the study after an acute condition known to cause AF (e.g. alcohol intake, thyrotoxicosis, acute infection, pericarditis, pulmonary embolism, cardiac surgery), - Patient with permanent AF defined as patients with an AF duration = 6 months (or duration unknown) and attempts to restore sinus rhythm no longer considered by the physician., - Patient with paroxysmal AF in whom cardioversion is not indicated, - Bradycardia 5.5 mmol/l, - Magnesemia < 0.8 mml/l (in patient with hypo-magnesemia, magnesium deficiency must be corrected before randomization), - Unstable angina pectoris (ischemic symptoms during the last 7 days) or recent myocardial infarction (MI) (< 6 weeks), - First degree family history of sudden cardiac death below age 50 years in the absence of coronary heart disease, - Second- or third- degree Atrio-Ventricular block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), - Ongoing potentially severe symptoms when in AF such as angina pectoris, transient ischemic attacks, stroke, syncope, as judged by the investigator, - Wolff-Parkinson-White Syndrome, - Previous ablation for atrial fibrillation or any planned ablation in the next following 2 months. Exclusion criteria to be checked at randomization - Bradycardia < 50 bpm on the 12-lead ECG before randomization, - Clinically overt congestive heart failure: o with New York Heart Association (NYHA) class III and IV heart failure, o with LVEF < 35%, o or NYHA class II with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic, o a
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of the study is to evaluate the rate of AF recurrences one month after randomization according to different timings of initiation of dronedarone.; Secondary Objective: The secondary efficacy objective is to evaluate the rate of AF recurrences two months after randomization. To assess the safety of the change from amiodarone to dronedarone To assess dronedarone safety ;Primary end point(s): The primary efficacy criterion is the rate of AF recurrences documented by two consecutive scheduled or unscheduled 12-lead ECG or TTEM performed approximately 10 minutes apart.;Timepoint(s) of evaluation of this end point: The primary efficacy criterion is the rate of AF recurrences one month after randomization according to different timings of initiation of dronedarone. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): The secondary efficacy endpoint is the rate of AF recurrences. Secondary safety endpoints ; Timepoint(s) of evaluation of this end point: The secondary efficacy endpoint is AF recurrences two months after randomization. Bradycardia/tachycardia: from V5 to V10 Laboratory tests: haematology:at V1 and V10. creatinine: V1, V7 and V10. INR: V1, V2, V3, V4, V5, V7, V8, V9 and V10. Thyroid function tests: at V1 and V10 Hepatic laboratory assessment:V1, V4, V5, V7, V9 and V10. ECG parameters: at each visit Adverse events, adverse events of special interest (AESIs), SAEs: all along the study. | — |
Countries
Australia, Austria, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Portugal, Spain, Switzerland, Taiwan, Turkey, United Kingdom
Contacts
Public ContactMedical Information
sanofi-aventis Groupe
Outcome results
None listed